Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Binder

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Leukemia|October 27, 2021
Mortality trends in multiple myeloma after the introduction of novel therapies in the United StatesMoritz Binder, Bharat Nandakumar, S Vincent Rajkumar, et al.
Blood Cancer Discovery|October 17, 2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3Mariateresa Fulciniti, Yao Yao, Tommaso Perini, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Frontiers in Endocrinology|July 8, 2022
Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal OutcomeEli Muchtar, Matthew T Drake, Nelson Leung, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
Leukemia|October 27, 2021
Mortality trends in multiple myeloma after the introduction of novel therapies in the United StatesMoritz Binder, Bharat Nandakumar, S Vincent Rajkumar, et al.
Blood Cancer Discovery|October 17, 2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3Mariateresa Fulciniti, Yao Yao, Tommaso Perini, et al.
Pageof 10